Galapagos has developed a target discovery platform that provides novel starting points for drug and antibody therapies, thereby addressing the industry’s need for innovative, disease-modifying medicines. Galapagos is exploiting this platform in disease areas for which there is a clear need for better medicines, such as bone and joint diseases, bone metastasis, cachexia, anti-infectives and metabolic diseases. To enable the progression of a broad portfolio of programs, Galapagos has established risk sharing alliances in specific disease areas with GlaxoSmithKline, Janssen Pharmaceutica, Eli Lilly and Merck and Co. Through an alliance with MorphoSys, Galapagos is also developing new antibody therapies in bone and joint diseases. Galapagos’ service division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharma, biotech and patient foundations - encompassing target and drug discovery through to the delivery of pre-clinical candidates. More info at: www.glpg.com.